GlycoMimetics GAAP EPS of -$0.17 in-line
Seeking Alpha News (Fri, 10-May 2:25 AM ET)
Business Wire (Mon, 6-May 6:00 AM ET)
GlycoMimetics to Report First Quarter 2024 Financial Results on May 9, 2024
Business Wire (Thu, 25-Apr 7:00 AM ET)
GlycoMimetics Reports Highlights and Financial Results for Fourth Quarter and Full Year 2023
Business Wire (Wed, 27-Mar 7:00 AM ET)
GlycoMimetics to Report Fourth Quarter and 2023 Full Year Financial Results on March 27, 2024
Business Wire (Wed, 13-Mar 7:00 AM ET)
GlycoMimetics to Participate in Upcoming Cowen 44th Annual Health Care Conference
Business Wire (Mon, 26-Feb 7:00 AM ET)
GlycoMimetics Inc is a clinical-stage biotechnology company. It is focused on the discovery and development of novel glycomimetic drugs to address unmet medical needs resulting from diseases in which carbohydrate biology plays a key role. Glycomimetics are molecules that mimic the structure of carbohydrates involved in important biological processes. Using expertise in carbohydrate chemistry and knowledge of carbohydrate biology, the company is developing a pipeline of proprietary glycomimetics that may inhibit disease-related functions of carbohydrates, such as the roles it play in inflammation, cancer, and infection.
Glycomimetics trades on the NASDAQ stock market under the symbol GLYC.
As of May 14, 2024, GLYC stock price climbed to $0.27 with 1,117,587 million shares trading.
GLYC has a beta of 0.62, meaning it tends to be less sensitive to market movements. GLYC has a correlation of 0.00 to the broad based SPY ETF.
GLYC has a market cap of $17.41 million. This is considered a Sub-Micro Cap stock.
In the last 3 years, GLYC stock traded as high as $4.16 and as low as $.26.
The top ETF exchange traded funds that GLYC belongs to (by Net Assets): VTI, VXF, IWC, AVSC, DFAC.
GLYC has underperformed the market in the last year with a price return of -85.9% while the SPY ETF gained +28.2%. GLYC has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -91.3% and -82.6%, respectively, while the SPY returned +5.7% and +2.1%, respectively.
GLYC support price is $.24 and resistance is $.28 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that GLYC stock will trade within this expected range on the day.